⌕
SRX Global · SRXH · NYSE
Tenet 24 · Weak
Compare
$1.03+3.00%At closeTenet 24 · Weak
$1.03+0.03 (+3.00%)
At close: Nov 19, 2026, 4:00 PM ET· NYSE · USD

SRX Global (SRXH) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireOct 30, 2026 · 15:16 ETCOMPANY'S OWN WORDS
SRX Global Provides Update on Balance Sheet and Share Buyback

NORTH PALM BEACH, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in …

● GlobeNewsWireOct 26, 2026 · 09:05 ETCOMPANY'S OWN WORDS
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics…

● GlobeNewsWireOct 8, 2026 · 08:35 ETCOMPANY'S OWN WORDS
SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform

New platform to be launched with managers from Millennium Management, Balyasny and Citadel, designed to enable the next generation of proprietary traders under Eric Jackson's leadership New platform to be launched with m…

● GlobeNewsWireOct 7, 2026 · 15:00 ETCOMPANY'S OWN WORDS
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologi…

● GlobeNewsWireOct 6, 2026 · 16:20 ETCOMPANY'S OWN WORDS
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim

SRX to dividend ETF holdings to shareholders  Initial ETF to feature an actively managed digital asset hedging strategy powered by EMJX's proprietary AI technology NORTH PALM BEACH, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) -…

● GlobeNewsWireSep 24, 2026 · 12:30 ETCOMPANY'S OWN WORDS
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)

SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones fo…

● GlobeNewsWireSep 23, 2026 · 16:05 ETCOMPANY'S OWN WORDS
SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar

NORTH PALM BEACH, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in…

● GlobeNewsWireSep 3, 2026 · 08:15 ETCOMPANY'S OWN WORDS
SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company

NORTH PALM BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in…

● GlobeNewsWireAug 31, 2026 · 07:30 ETCOMPANY'S OWN WORDS
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers

The Debt investment is expected to accelerate development of CERo's lead therapeutic CER-1236 for hematological cancers The Debt investment is expected to accelerate development of CERo's lead therapeutic CER-1236 for he…

No upcoming events in the feeds.

ANT13−7.0%
AAPL8+0.3%
FOX6−2.9%
META6−2.2%

Article counts from the last market-wide feed page, across every symbol we track and not just SRXH · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.